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Abstract
Mechanistic research suggests a unique evolutionary relationship between complex milk oligosaccharides and cognate bifidobacteria enriched in breast-fed
infants. Bovine milk oligosaccharides (BMO) were recently identified as structurally and functionally similar to human milk oligosaccharides. The present
single-blind three-way crossover study is the first to determine the safety and tolerability of BMO consumption by healthy human participants (n 12) and its
effects on faecal microbiota and microbial metabolism. Participants consumed each supplement (placebo-control; low- and high-BMO doses) for eleven
consecutive days, followed by a 2-week washout period prior to initiating the next supplement arm. Low and high BMO doses were consumed as 25 and
35 % of each individual’s daily fibre intake, respectively. Safety and tolerability were measured using standardised questionnaires on gut and stomach dis-
comfort and stool consistency. Faecal extracts were profiled for bacterial populations by next-generation sequencing (NGS) and bifidobacteria presence was
confirmed using quantitative PCR. Urine was analysed for changes in microbial metabolism using nuclear magnetic resonance spectroscopy (1H-NMR).
Consumption of both the low and high BMO doses was well tolerated and did not change stool consistency from baseline. Multivariate analysis of the NGS
results demonstrated no change in faecal microbiota phyla among the placebo-control and BMO supplement groups. In conclusion, BMO supplementation
was well tolerated in healthy adults and has the potential to shift faecal microbiota toward beneficial strains as part of a synbiotic treatment with probiotic
cultures that selectively metabolise oligosaccharides.
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The intestinal microbiome is recognised as an important deter-
minant of health and has become a critical area of study for
functional foods. Probiotics and prebiotics are widely used
alternative therapies for intestinal health. Plant-based prebio-
tics, such as inulin and fructo-oligosaccharides, are commer-
cially available, but their simple structure may lead to
non-selective growth of gut microbes. Thus, there is an
unmet need for selective, scientifically validated strategies to
guide the intestinal microbiome towards protective popula-
tions. Mechanistic research has led to the understanding
of the unique evolutionary relationship between complex
human milk oligosaccharides (HMO) and cognate bifidobac-
teria enriched in breast-fed infants(1). HMO are abundant in
human milk (1–2 %, w/v), and are structurally diverse.
Because humans lack the glycolytic enzymes in the gut to
digest HMO, these indigestible carbohydrates reach the
Abbreviations: BMO, bovine milk oligosaccharides; GI, gastrointestinal; HMO, human milk oligosaccharides; HNC, Human Nutrition Center; OTU, operational taxonomic
unit.
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colon intact(2–4) and function as selective prebiotics for bene-
ficial gut bifidobacteria(5–8). The enrichment of bifidobacteria
in breast-fed infants is believed to be driven in part through
the prebiotic effect of HMO. Interestingly, bovine milk oligo-
saccharides (BMO), a commercially accessible alternative to
HMO, have been recently identified as structurally and func-
tionally similar to HMO(9–13), and are preferentially consumed
by select bifidobacteria(14). BMO can be captured from whey
permeate as a waste stream from whey protein concentrate
production. Capturing the value from this waste stream as a
high-value supplement and/or product for both targeted
at-risk populations and for the general public could result in
significant, and direct economic revenue and health benefits.
This study was designed to determine if dairy-derived BMO
were safe and well-tolerated when consumed by healthy
human participants. The second objective was to determine
if two daily doses of BMO enrich faecal bifidobacteria levels.
We hypothesised that a diet containing BMO will be well tol-
erated in a healthy adult population, and will effectively enrich
beneficial gut microbes and/or their metabolism. This bacter-
ial enrichment could coincide with markers of BMO metabol-
ism and confer intestinal health benefits in populations with
intestinal distress. This pilot study was the first to document
the selective stimulation of protective bifidobacteria in vivo
and is the first step in establishing an intestinal health dossier




The sample size for this study was based on data by Bouhnik
et al.(15) in which intake of both 5 and 10 g/d of short-chain
fructo-oligosaccharides by eight different adults over 8 d
resulted in significantly higher faecal bifidobacteria by at least
1 log compared with baseline and was well tolerated.
Individuals living in the Davis, CA area were recruited to par-
ticipate in the study and thirty-six individuals were screened for
enrolment into the study. Inclusion criteria included: healthy
men and women aged 18–40 years, normal fasting glucose
and lipid values, fibre intake <30 g/d, faecal bifidobacterial
populations <25 % of total faecal bacteria, born by vaginal
birth and breastfed for a minimum of 2 months. Exclusion cri-
teria were: regular consumption of high-fibre cereals or fibre
supplements, or yogurt containing bifidobacteria (within the
last 4 weeks); lactose intolerance or allergies to dairy products
or wheat; tobacco use; pregnancy or lactation; presence of
gastrointestinal (GI)/malabsorption disorders or autoimmune
disease; or use of prescription or over-the-counter medica-
tions/supplements that include pre- and probiotics, corticos-
teroids, anti-obesity agents, laxatives, antibiotics and lipid
altering medications. A total of sixteen individuals who met
pre-screening criteria visited the UC Davis Ragle Human
Nutrition Center (HNC) for a screening visit to provide a fast-
ing blood sample and a stool sample, and to have their height,
weight, blood pressure and heart rate measured. Blood sam-
ples were analysed for fasting lipid and glucose profiles, and
stool samples were analysed for faecal bifidobacteria.
Participants also completed an online Muldoon Omega-3
Food Frequency Questionnaire that contains 444 items
(Modified Block 2006-Bodnar FFQ, 2006; NutritionQuest/
Block Dietary Data Systems) in order to have their average
daily fibre intake estimated. Twelve participants eligible for
enrolment were instructed to complete a Baecke physical activ-
ity questionnaire(16) and detailed health history questionnaire.
The Baecke physical activity questionnaire was used to account
for energy expenditure in estimating the appropriate energy
intake level used to calculate the doses of each dietary treat-
ment. The UC Davis Institutional Review Board approved
all aspects of the study and written informed consent was
obtained from all participants prior to study procedures.
This study was registered on clinicaltrials.gov (NCT01814540).
Study protocol
This was a single-blind, placebo-controlled, crossover trial with
three dietary treatment arms administered in the following
order for eleven consecutive days each (day 0 to day 10): (1)
placebo-control; (2) low-BMO; and (3) high-BMO doses.
Each treatment arm was followed by a 2-week washout. The
dietary treatments were not randomised in order to eliminate
possible carry-over effects by the BMO supplement.
Participants arrived after a 10–12 h overnight fast to the
HNC on each weekday morning during each supplement
arm, filled out questionnaires to determine compliance and
GI tolerability and consumed their morning supplement
dose with a breakfast ad libitum consisting of any of the follow-
ing: coffee, tea, milk, sugar, juice, fruit, hot or cold cereals;
bagels, cream cheese, butter or jam; waffles and syrup; break-
fast burritos or breakfast sandwiches. The doses of each treat-
ment were calculated using the Institute of Medicine’s
recommendation for daily fibre intake (14 g of dietary fibre
per 1000 kcal (4184 kJ) consumed)(17). Both the placebo-
control and low-BMO treatments were calculated as the num-
ber of g of carbohydrate equivalent to 25 % of daily fibre
intake based on individual energy consumption and the
high-BMO dose was calculated as 35 % of daily fibre intake.
The placebo-control was composed of Polycose, a glucose
polymer powder (Abbott Nutrition) and the pure lactose-free
BMO powder was supplied by Hilmar Ingredients. The oligo-
saccharide composition for the lactose-free BMO supplement
powder can be found in Table 1. The glucose polymer and
BMO powder were each combined with equal parts of
Nesquik chocolate powder and stored in sealable sachets
prior to administering to participants. Participants were
instructed to consume their daily treatment dose split as two
daily doses in the morning with breakfast and before bedtime.
Starting on the morning of day 0 (baseline) and on each week-
day morning up to and including day 10, participants arrived at
the HNC and were administered their half daily dose of the
treatment mixed with 120 ml of lactose-free milk by study per-
sonnel with breakfast. Participants were provided with lactose-
free milk for mixing their evening doses at home. Lactose-free
milk was used to reduce any prebiotic effects of lactose in indi-
viduals with subclinical symptoms of lactose intolerance and
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ensure that observed outcomes are solely due to milk oligosac-
charides. Participants were instructed to consume both the
morning and evening doses at home on weekend study days.
Diet and dietary data
Throughout the entire study period, participants were
instructed to refrain from consuming high-fibre diets and
fibre supplements and to avoid consumption of yogurt
containing Bifidobacterium. On the morning of each study day
participants filled out a questionnaire regarding their intake
of any study-prohibitive foods/supplements/medications
within the past 24 h, which was used to determine compliance.
To establish a baseline for habitual dietary intake, participants
filled out a 3-d diet record to represent two weekdays and
one weekend day during the 1-week run-in period prior to ini-
tiating each supplement arm. Dietary data were analysed using
FoodWorks Nutrient Analysis Software, version 14 (Nutrition
Company).
Gut tolerability and stool consistency
The modified Pedersen GI questionnaire was used throughout
the study to estimate GI tolerability, which prompted partici-
pants to rate their feelings on gut symptoms including: overall
GI discomfort; bothersomeness; rumbling stomach; rumbling
gut; belching; nausea; stomach cramps; gut cramps; bloated-
ness; acid reflux; flatulence; diarrhoea; vomiting; and constipa-
tion(18). GI symptoms were rated on an interval scale from 0 to
10, with 0 indicating an absence of the symptom, 1–3 as ‘mild’
discomfort; 4–6 as ‘moderate’ discomfort, 7–9 as ‘severe’ dis-
comfort and 10 as ‘extreme’ discomfort. Participants were also
prompted to record the duration of the longest-lasting symp-
tom. The GI questionnaire was administered to participants on
five occasions on days 0–10 and once on day 11 of each
supplement arm. On days 0–10, participants filled out the
GI questionnaire after a 10–12 h overnight fast before and
1, 3, 6 and 9 h after consuming the supplement with breakfast.
To establish a baseline for GI symptoms, participants filled
out the GI questionnaire 1 week before initiating each supple-
ment arm as a run-in period for five consecutive days in the
morning before consuming any food or liquids. GI tolerability
responses were separated into two groups for analysis pur-
poses: run-in and intervention. Run-in scores were calculated
by averaging the responses to each question for the 5 d of
questionnaires. Intervention scores were calculated by aver-
aging the responses to each question at 1, 3, 6 and 9 h after
the morning treatment for the 11 d of each study arm. To
determine if BMO intake altered stool consistency, participants
filled out the Bristol Stool Scale(19). The Bristol Stool Scale is a
seven-point scale that describes hardness to softness of stool
with images and worded descriptions. Stool types 1–2 indicate
constipation; stool types 3 and 4 are ideal stools (especially
type 4), as they are easy to defecate while not containing any
excess liquid; and stool types 5, 6 and 7 lean toward diarrhoea.
Bowel movements produced were self-recorded, and partici-
pants recorded their date, time, and consistency or type.
Participants filled out the Bristol Stool Scale daily for 7 d
before initiating each study arm and during days 1–10 of
each treatment arm. Stool type responses were separated
into two groups for analysis purposes: run-in and intervention.
Run-in scores were calculated by averaging stool type
responses on days −7 to −1 for each treatment arm.
Intervention scores were calculated by averaging the responses
during the 11 d of each study arm.
Anthropometric and clinical measurements
Height, weight, blood pressure, heart rate and body tempera-
ture were measured at the HNC on day 0 and day 11 of
each treatment arm. Height and weight were used to calculate
each participant’s BMI (kg/m2).
Samples collected
Blood was collected from participants on days 0 and 11 after a
10–12 h overnight fast. Participants were instructed to collect
their stool samples at home at three time points: days −2, 4
and 11 of each treatment arm. Since stool samples cannot
be collected on demand, participants were instructed to collect
the samples within 1–2 d of each time point. Samples were
stored in participants’ home freezers until transported on ice
packs by the participant or picked up by study personnel.
Participants were instructed to collect first morning urine sam-
ples at home on days 0, 4 and 11 prior to transport on ice
packs to the HNC. Participants were instructed to refrain
from consuming any alcohol 24 h prior to stool, urine and
blood collections, and to refrain from consuming non-
steroidal anti-inflammatory drugs, fish, or oils derived from
fish, borage, evening primrose or krill 24 h prior to blood col-
lection. Blood samples were centrifuged for 20 min at 1300 g
and plasma and serum were separated from the erythrocytes.
Additional plasma and serum samples were portioned into








505·1763 3 Hex 22602918·2 19·9
546·2029 2 Hex 1 HexNAc 10677827·66 9·4
634·2189 2 Hex 1 NeuAc 51947266·34 45·7
667·2293 4 Hex 6619221·77 5·8
675·2454 1 Hex 1 HexNAc 1 NeuAc 429503·96 0·4
691·2404 1 Hex 1 HexNAc 1 NeuGc 741547·2 0·7
708·2557 3 Hex 1 HexNAc 4314541·64 3·8
749·2822 2 Hex 2 HexNAc 807377·23 0·7
796·2717 3 Hex 1 NeuAc 1033609·11 0·9
829·2821 5 Hex 4707544·62 4·1
870·3085 4 Hex 1 HexNAc 3588316·79 3·2
911·3352 3 Hex 2 HexNAc 838388·74 0·7
991·335 6 Hex 2944520·4 2·6
1073·388 4 Hex 2 HexNAc 823533·79 0·7
1114·415 3 Hex 3 HexNAc 686701·61 0·6
1153·387 7 Hex 697138·37 0·6
1315·440 8 Hex 264710·79 0·2
* Hex represents glucose or galactose; molecular weight 162·0528. HexNAc
represents N-acetyl glucosamine or N-acetyl galactosamine; molecular weight
203·0794. NeuAc represents sialic acid; molecular weight 291·0954.
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aliquots and stored at −80°C until analysed. Plasma lipid
(TAG; total, LDL- and HDL-cholesterol) and glucose profiles
were analysed by the UC Davis Medical Center Pathology
Laboratory (Sacramento, CA). Stool samples were stored at
−80°C until analysed for total and bifidobacterial measure-
ments. Urine samples were portioned into aliquots and stored
at −80°C until analysed for urinary metabolites.
Compliance
On the morning of each study weekday, participants filled out
a questionnaire regarding their intake of any study-prohibitive
foods/supplements/medications within the past 24 h and
returned their empty evening supplement sachet from the
night before. If participants did not consume prohibitive
foods/supplements/medications and returned the empty
evening dose supplement sachet, they were cleared for compli-
ance and engaged in study activities and received their evening
supplement dose for that evening.
Faecal microbiota
Faecal DNA extraction. DNA was extracted from 150 mg of
stool sample using the ZR Fecal DNA MiniPrep kit (ZYMO)
in accordance with the manufacturer’s instructions, which
included a bead-beating step using a FastPrep-24 Instrument
(MP Biomedicals) for 2 min (23°C) at 6·5 m/s.
Next-generation sequencing. DNA samples were prepared as
previously described(20) with the following modifications.
Universal barcoded primers with Illumina sequencing adapters
(adapters are italicised and the barcode is highlighted in bold)
V4F (5′-AATGATACGGCGACCACCGAGATCTACAC
TCTTTCCCTACACGACGCTCTTCCGATCT ACTGCTG
AGTGTGCCAGCMGCCGCGGTAA-3′) and V4Rev (5′-C
AAGCAGAAGACGGCATACGAGATCGGTCTCGGCAT
TCCTGCTGAACCGCTCTTCCGATCTCCGGACTACHVG
GGTWTCTAAT-3′) were used to PCR amplify the V4 region
of the 16S rRNA gene(20). PCR reactions were carried out in
triplicate and contained 12·5 µl 2x GoTaq Green Master
Mix (Promega), 1·0 µl 25 mM-MgCl2, 8·5 µl water, 0·5 µl
forward and reverse primers (10 µM final concentration) and
2·0 µl genomic DNA. The triplicate reactions were combined
and cleaned and DNA concentrations were quantified using
the PicoGreen dsDNA Kit. An equimolar composite sample
mixture was made, gel purified, and sequenced at the
University of California DNA Technologies Core Facility on
an Illumina MiSeq sequencing platform.
Bifidobacterium quantitative PCR. Levels of Bifidobacterium
were measured by quantitative PCR (qPCR) using the
methods of Penders et al.(21), with primers Bif-F and Bif-R
and probe Bif-P and performed on a 7500 Fast Real-Time
PCR System (Applied Biosystems). Assays contained 10 µl 2x
TaqMan Universal PCR master mix (Applied Biosystems), 1 µl
each forward and reverse primers and TaqMan probe, 5 µl
water, and 2 µl genomic DNA. All reactions were carried out
in triplicate with a non-template control.
Sequence analysis. The QIIME software package (version
1.5.0) was used to analyse the results of the Illumina
sequencing run. Illumina V4 16S rRNA gene sequences
were demultiplexed and quality filtered using the QIIME
software package(22). Reads were truncated after a maximum
number of three consecutive low-quality scores. After quality
trimming, reads were removed from analysis if they were
<60 bp and the number of ambiguous bases were >3. The
minimum number of consecutive high-quality base calls to
include a read (per single-end read) as a fraction of the
input read length was set at 0·70. Similar sequences were
clustered into operational taxonomic units (OTU) with
UCLUST software(23) and minimum identity of 97 %. The
most abundant sequence was chosen to represent each
OTU. Taxonomy was assigned to each OTU with the
Ribosomal Database Project (RDP) classifier(24) with a
minimum confidence threshold of 80 % and the RDP
taxonomic nomenclature(25). OTU representatives were aligned
against the Greengenes core set(26) with PyNAST software(27)
with a minimum alignment length of 75 bp and a minimum
identity of 75 %.
Urinary metabolomics
First morning urine samples were analysed by NMR spectro-
scopy. Urine samples were prepared for NMR analysis by
the addition of 65 µl of the internal standard DSS-d6
(2,2,3,3,4,4-d6–3-(trimethylsilyl)-1-propane sulfonic acid) (at
5 mM) to 585 µl urine, and the pH was adjusted to approxi-
mately 6·8 by the addition of small amounts of NaOH or
HCl. A portion of the sample (600 µl) was placed into a 5
mm NMR tube as described in Slupsky et al.(28,29). Samples
were run on a Bruker 600 MHz NMR spectrometer using
the NOESY pulse sequence with water saturation of 2·5 s dur-
ing the prescan delay, a mixing time of 100 ms, 12 parts per
million sweepwidth, 2·5 s acquisition time, eight dummy
scans, and thirty-two transients. All spectra were zero-filled
to 128k data points, and a weighted Fourier transform with
application of a 0·5 Hz line-broadening function and manual
phase and baseline correction. Metabolite profiles were derived
from targeted profiling analysis using NMRSuite v7.6 Profiler
(Chenomx, Inc.) as described(30). All compounds in the data-
base have been verified against known concentrations of refer-
ence NMR spectra of the pure compounds and have been
shown to be reproducible and accurate(28,31).
Statistics
The change in gut tolerability, stool consistency (intervention –
run-in) and anthropometric data (day 11 – day 0), dietary
nutrient data collected during the run-in period and bifidobac-
teria measured by qPCR on day 0, day 4 and day 11 were
checked for normality using the SPSS Explore procedure
and were transformed appropriately (SPSS v. 22). Normally
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distributed data for the change in gut tolerability, stool consist-
ency, anthropometric and nutrient variables were analysed by
ANOVA. Repeated-measures ANOVA was performed to
determine the effect of time, treatment and time × treatment
on log-transformed faecal bifidobacteria levels. If repeated-
measures ANOVA demonstrated a significant time effect
among day 0, day 4 or day 11, a paired-samples two-tailed t
test was performed to identify the treatment group that
reached significance. One-way ANOVA was performed on
faecal bifidobacteria at day 0 to determine the presence of
a carry-over effect among the three treatment arms.
Multiple-comparisons analysis with a Bonferroni adjustment
was used to determine differences among the three treatment
groups for all ANOVA (P < 0·05). To determine differences in
bacterial populations among the three treatments, OTU-based
and phylogenetic α-diversity metrics were calculated using rar-
efied datasets. Specifically, the number of sequences in the
smallest sample set was drawn randomly ten times from
each sample set and the averages reported. Unweighted and
weighted UniFrac distances (i.e. phylogenetic β-diversity
metrics) were calculated between all pairs of samples.
UniFrac-based sample clustering was performed using
principal coordinates analysis. To determine which bacterial
populations drive separations between the treated and
untreated classes, we conducted a linear discriminate analysis
(LDA) using the LDA effect size (LEfSe) method(32). Urine
metabolite concentrations were normalised to creatinine and
log10 transformed prior to analysis. For group analyses, days
4 and 11 of the placebo-control, low-dose and high-dose
BMO arms were compared. Multivariate statistical analysis
(principal components analysis; PCA) implemented in
Simca-P+12 was used to determine if clustering occurred
with supplement. Data were mean centred and unit variance
scaled. One-way ANOVA with multiple-comparisons analysis
with a Bonferroni adjustment was used to confirm significance
of clustering in the PCA plot using SPSS v. 22. One-way
ANOVA with multiple-comparisons analysis with a Bonferroni
adjustment was used to determine the effect of the supplement
groups on the percentage change of urinary metabolites
((day 11 – day 0/day 0) × 100 %) (P< 0·05).
Results
Subjects
A total of twelve participants were enrolled in the trial (n 9
males, n 3 females). All twelve participants complied and com-
pleted the placebo-control arm, ten participants complied and
completed the low-BMO arm, and nine participants complied
and completed the high-BMO arm. One participant was dis-
qualified from participation in the study in the middle of the
second supplement arm for missing several sample collec-
tions. A second participant was disqualified from participation
in the study in the middle of the second supplement arm after
initiating a course of antibiotics to treat streptococcal pharyn-
gitis. A third participant dropped out of the study due to per-
sonal commitments after completing the first and second
treatment arms. Data are reported for all nine participants
who completed all three supplement arms (n 6 males, n 3
females).
Dietary treatment doses
During the high-BMO arm, participants consumed signifi-
cantly higher BMO powder than in the low-BMO arm
(mean intake: 13·1 v. 9·4 g/d; P < 0·0005). Participants in
the low-BMO and placebo-control groups consumed similar
amounts of BMO and glucose polymer powder, respectively
(Table 2).
Subject characteristics
Participants’ age, change in weight, BMI and blood pressure
between each treatment arm were not different (Table 3).
Nutrient intake data
Nutrient intake data estimated from 3-d diet records filled out
by participants the week before each treatment arm are pre-
sented in Table 4. Of the nutrients estimated, only reported
total fat (g/d) and saturated fat (g/d) intake were significantly
higher before the placebo-control v. the high-BMO arm
(P < 0·05) (Table 4). Reported energy intake was higher before
the placebo-control v. high-BMO arm but this difference was
not statistically significant (P = 0·085).
Gut tolerability and stool consistency
The mean, standard deviations and ranges for the fourteen GI
responses are reported in Tables 5–7. The mean difference
between intervention and run-in periods for each of the
fourteen symptoms listed in the GI questionnaire were not
statistically different (data not shown). Thus, BMO supple-
mentation was equally tolerable compared with the placebo-
control. In addition, stool type was not different among the
three supplement groups (Fig. 1). The ideal stool consistency
(type 4) remained consistent throughout each treatment arm.
Faecal microbiota
Next-generation sequencing of 16S rRNA extracted and amp-
lified from subjects’ stool was used to determine faecal micro-
biota profiles (see Materials and methods). For each of the
nine participants who completed the study, the faecal profiles
from the placebo-control and high-BMO treatments were
Table 2. Supplement amount (g) per treatment arm
(Mean values, standard deviations and ranges; n 9 per treatment arm)
Treatment Mean SD Minimum Maximum
Placebo-control 9·5 1·6 7·0 11·6
Low-BMO 9·4 1·5 6·9 11·5
High-BMO 13·1* 2·2 9·6 16·1
BMO, bovine milk oligosaccharides.
* Mean value was significantly different from those of the placebo-control and
low-BMO treatments (P < 0·0005).
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Table 3. Baseline participant characteristics prior to each supplemental arm
(Mean values, standard deviations and ranges; n 9 per treatment arm)
Placebo-control Low-BMO High-BMO
Mean SD Minimum Maximum Mean SD Minimum Maximum Mean SD Minimum Maximum
Age (years) 23·9 3·2 19·0 30·0 23·9 3·0 19·0 30·0 23·9 3·2 19·0 30·0
Weight (kg) 69·1 14·1 49·9 100·5 69·4 14·0 49·6 99·7 69·7 13·3 50·0 97·4
BMI (kg/m2) 22·5 3·3 19·0 30·3 22·6 3·2 19·1 30·0 22·7 2·9 19·3 29·3
Systolic blood pressure (mmHg) 123·6 8·6 110·0 136·0 116·4 11·8 100·0 132·0 118·6 11·8 102·0 141·0
Diastolic blood pressure (mmHg) 77·6 5·3 70·0 87·0 74·1 8·4 61·0 88·0 73·7 4·4 68·0 81·0
BMO, bovine milk oligosaccharides.
Table 4. Habitual nutrient intake prior to each supplemental arm
(Mean values and standard deviations; n 9 per treatment arm)
Placebo-control Low-BMO High-BMO
Mean SD Mean SD Mean SD
Energy
kcal 2379 568 2094 353 1857 478
kJ 9954 2377 8761 1477 7770 2000
Protein (g) 96·2 21·8 83·9 28·4 77·1 25·3
Protein (% energy) 16·2 1·2 15·8 3·0 16·7 3·9
Carbohydrate (g) 266·7 64·2 243·7 35·4 229·9 71·9
Carbohydrate (% energy) 45·2 6·1 47·4 8·9 49·2 6·5
Dietary fibre (g) 21·5 6·1 22·4 6·5 19·9 5·7
Total sugars (g) 86·6 15·7 97·1 31·8 76·4 34·0
Total fat (g) 84·6a 17·6 74·4a,b 20·7 60·2b 12·4
Fat (% energy) 32·8 6·3 32·1 8·3 30·1 6·4
Saturated fat (g) 29·9a 8·0 24·2a,b 6·8 21·0b 7·6
Saturated fat (% energy) 11·6 2·8 10·4 2·7 10·4 3·3
Monounsaturated fat (g) 26·3 9·7 26·3 11·2 18·7 3·6
Polyunsaturated fat (g) 12·4 6·2 13·8 4·2 9·5 2·0
Cholesterol (mg) 318·0 138·9 225·4 87·5 247·0 115·6
Trans-fatty acids (g) 0·6 0·8 0·2 0·2 0·1 0·2
Total n-3 fatty acids (g) 1·3 0·7 1·5 0·9 1·0 0·3
Total n-6 fatty acids (g) 1·0 1·1 1·7 1·1 1·3 1·2
n-6:n-3 ratio 0·9 0·9 1·2 0·7 1·3 1·0
Alcohol (g) 21·3 34·5 19·6 19·7 14·4 14·3
BMO, bovine milk oligosaccharides.
a,b Mean values with unlike superscript letters were significantly different (P < 0·05).
Table 5. Gut tolerability in response to the placebo-control arm
(Mean values, standard deviations and ranges; n 9 per treatment arm)
Run-in Intervention
GI symptoms Mean SD Minimum Maximum Mean SD Minimum Maximum
Overall GI 0·8 1·0 0·0 2·5 0·3 0·4 0·0 1·2
Bothersome 0·6 0·7 0·0 2·0 0·2 0·2 0·0 0·5
Stomach rumble 0·2 0·7 0·0 2·3 0·1 0·2 0·0 0·6
Gut rumble 0·3 0·7 0·0 2·0 0·1 0·1 0·0 0·2
Belching 0·0 0·1 0·0 0·2 0·1 0·1 0·0 0·2
Nausea 0·0 0·1 0·0 0·3 0·0 0·0 0·0 0·1
Stomach cramps 0·1 0·2 0·0 0·5 0·0 0·0 0·0 0·1
Gut cramps 0·0 0·1 0·0 0·3 0·0 0·1 0·0 0·1
Bloated 0·5 0·7 0·0 2·3 0·1 0·2 0·0 0·4
Acid reflux 0·0 0·0 0·0 0·0 0·0 0·1 0·0 0·2
Flatulence 0·3 0·5 0·0 1·5 0·3 0·4 0·0 1·1
Diarrhoea 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·1
Vomiting 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0




compared. LEfSe analysis of the Illumina sequencing data sug-
gests that the microbiota did not change in response to the
treatments but the microbiota did cluster according to subject.
The lack of a treatment effect was expected after identifying
large variation and bacterial diversity in this group of healthy
adults. The only taxa that showed changes between treated
(high-BMO treatment) and untreated (placebo-control) was
Peptostreptococcaceae, with a LEfSe of 3·4 (P < 0·05) (Fig. 2).
Faecal bifidobacteria
qPCR analysis on DNA isolated from faecal extracts was used
to determine if BMO supplementation influenced faecal bifi-
dobacteria levels. Repeated-measures ANOVA identified a sig-
nificant trend for the effect of time (P= 0·06) but not any
treatment or time × treatment effects on faecal bifidobacteria
levels (Fig. 3). When repeated-measures ANOVA was per-
formed to only compare two time points (day 0 and day 4),
the statistical significance for time increased to P= 0·01 yet
the effect of time disappeared when day 0 and day 11 were
compared. Thus the effect of time was observed between
day 0 and day 4 but not apparent between day 0 and day
11, suggesting that by day 11, the total level of bifidobacteria
returned back to baseline for each of the three treatment
Table 6. Gut tolerability in response to the low-bovine milk oligosaccharide arm
(Mean values, standard deviations and ranges; n 9 per treatment arm)
Run-in Intervention
GI symptoms Mean SD Minimum Maximum Mean SD Minimum Maximum
Overall GI 0·4 0·5 0·0 1·4 0·4 0·4 0·0 1·4
Bothersome 0·2 0·4 0·0 1·4 0·3 0·3 0·0 0·7
Stomach rumble 0·0 0·1 0·0 0·2 0·0 0·0 0·0 0·0
Gut rumble 0·2 0·4 0·0 1·2 0·1 0·1 0·0 0·3
Belching 0·1 0·1 0·0 0·4 0·0 0·1 0·0 0·1
Nausea 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0
Stomach cramps 0·1 0·2 0·0 0·6 0·0 0·0 0·0 0·0
Gut cramps 0·1 0·3 0·0 0·8 0·0 0·1 0·0 0·2
Bloated 0·1 0·3 0·0 1·0 0·2 0·2 0·0 0·5
Acid reflux 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0
Flatulence 0·3 0·5 0·0 1·4 0·4 0·4 0·0 1·3
Diarrhoea 0·0 0·0 0·0 0·0 0·1 0·1 0·0 0·4
Vomiting 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·1
Constipation 0·0 0·1 0·0 0·4 0·1 0·2 0·0 0·6
GI, gastrointestinal
Table 7. Gut tolerability in response to the high-bovine milk oligosaccharide arm
(Mean values, standard deviations and ranges; n 9 per treatment arm)
Run-in Intervention
GI symptoms Mean SD Minimum Maximum Mean SD Minimum Maximum
Overall GI 0·2 0·4 0·0 1·0 0·4 0·6 0·0 1·8
Bothersome 0·2 0·3 0·0 1·0 0·3 0·3 0·0 0·8
Stomach rumble 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·1
Gut rumble 0·0 0·1 0·0 0·2 0·0 0·1 0·0 0·3
Belching 0·0 0·0 0·0 0·0 0·0 0·1 0·0 0·2
Nausea 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·1
Stomach cramps 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·1
Gut cramps 0·0 0·1 0·0 0·4 0·1 0·1 0·0 0·2
Bloated 0·1 0·2 0·0 0·7 0·2 0·3 0·0 0·8
Acid reflux 0·0 0·0 0·0 0·0 0·0 0·1 0·0 0·2
Flatulence 0·2 0·4 0·0 1·0 0·4 0·4 0·0 1·5
Diarrhoea 0·0 0·0 0·0 0·0 0·0 0·1 0·0 0·3
Vomiting 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0
Constipation 0·0 0·0 0·0 0·0 0·1 0·2 0·0 0·5
GI, gastrointestinal
Fig. 1. Self-report stool consistency levels by participants during the run-in (□)
and intervention (░) period by each study participant. Values are means (n 9
per supplemental arm), with standard deviations represented by vertical bars.
BMO, bovine milk oligosaccharides.
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arms. A significant difference for faecal bifidobacteria levels
between day 0 and day 4 by a paired-samples t test could
not be determined among any of the treatments.
Furthermore, faecal bifidobacteria levels were not different
at day 0 for each study arm, suggesting that there was not a
carry-over effect by the supplement.
Urinary metabolomics
NMR-based metabolomics was used to assess if changes in
urine metabolites could be observed with supplementation.
No difference between the low-BMO supplement and the
placebo-control could be observed. However, some clustering
along principal component 2 (PC2) of the urine after high
BMO intake could be observed (Fig. 4(A) and (B)). Analysis
of PC2 using repeated-measures ANOVA with Tukey’s
multiple-comparisons test revealed significance (P = 0·003).
Pairwise evaluation revealed no difference between placebo-
control and the low-BMO group (P = 0·7), but significant dif-
ferences between placebo-control and the high-dose BMO
group (adjusted P = 0·03), and between the low-BMO and
high-BMO groups (adjusted P= 0·005). We therefore com-
pared metabolite concentrations between the placebo-control
and high-BMO groups for the top variables that were
explained by PC2 (4-hydroxyphenylacetate, 1-methylhistidine,
cis-aconitate, trimethylamine N-oxide, 2-oxoglutarate, glutam-
ine, mannitol, and dimethyl sulfone). There were significant
differences for urinary cis-aconitate and 4-hydroxyphenylace-
tate at day 11 between the placebo-control and the high-
BMO groups (P < 0·05) and differences in urinary mannitol
at day 11 between the low- and high-BMO groups (P <
0·05) (Table 8). When these three urinary metabolites were
analysed as a percentage change from baseline, only urinary
cis-aconitate was significantly reduced in response to the
high-BMO compared with the placebo-control (P < 0·05)
(Fig. 5).
Discussion
In this study, we demonstrate for the first time that consump-
tion of whey-derived complex oligosaccharides by healthy par-
ticipants for eleven consecutive days was safe and well
tolerated. During all three treatment arms, GI tolerability
symptoms measured throughout each treatment arm did not
fluctuate from the run-in period. Additionally, the ideal stool
consistency (type 4) remained consistent throughout each
Fig. 2. Faecal relative abundance of the family Peptostreptococcaceae in
each participant in response to the placebo-control and high-bovine milk oligo-
saccharide (BMO) supplement arms on days 0 ( ), 4 ( ) and 11 (■) (n 9 per
supplemental arm). The linear discriminant analysis effect size between the
high-BMO and placebo-control groups for the faecal relative abundance of
the family Peptostreptococcaceae was 3·4 (P < 0·05).
Fig. 3. Faecal bifidobacteria levels at day 0 (□), day 4 ( ) and day 11 (░) in
response to the placebo-control (PC), low-bovine milk oligosaccharide (LB)
and high-bovine milk oligosaccharide (HB) supplement arms. Values are
means (n 9 per supplemental arm), with standard deviations represented by
vertical bars.
Fig. 4. Principal components (PC) analysis of urine metabolite concentrations
in different treatment arms. (A) Comparison of days 4 and 11 in the placebo-
control (○), low-dose ( ), and high-dose (●) bovine milk oligosaccharide
(BMO) groups. The variances along PC1 and PC2 were 42 and 5 %, respect-
ively. (B) Mean PC2 value for each of seven subjects who provided a urine
sample at all time points during all three treatment arms in the study, with
standard errors for days 4 and 11.
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study arm. This subject population was screened for healthy
GI systems which includes healthy bowel movements.
Hence it is not surprising that participants’ stool types did
not improve from ideal while consuming the BMO supple-
ment. The low-BMO dose ranged from 6·9 to 11·5 g/d and
matched the placebo-control dose that was derived from a
readily digestible carbohydrate. The high-BMO dose ranged
from 9·6 to 16·1 g/d which is within the dose range used in
plant-derived prebiotics. Yet, BMO consumption did not
alter GI symptoms from the run-in periods, unlike fructo-
oligosaccharides which increased GI intolerance from baseline
at doses above 10 g/d(15,33). In addition to enhancing GI dis-
comfort, structurally simple prebiotics have been shown to
non-selectively enrich other classes of faecal bacteria and not
just bifidobacteria(34–37).
While there are no commercial sources of these materials
today, the existing processing capabilities of cheese and whey
manufacturers can be employed to capture BMO from whey
permeate and produce sufficient amounts to perform large
randomised clinical studies in target populations. BMO
supplementation with probiotics was found to be well toler-
ated and increase intestinal bifidobacteria in infants who
were formula fed(38).
Participants’ metabolic responses did not change over the
course of the study period. This is unsurprising due to the
short duration of each study arm (11 d) and 2-week washout
period. Of the urinary metabolites measured, only cis-aconitate
changed significantly in response to the high-BMO compared
with the placebo-control arm. This could be due to differences
in diet that we observed between the placebo-control and the
high-dose supplement arm. Indeed, we observed that total
saturated fat and total fat were higher in the placebo-control
arm v. the high-dose BMO arm. Decreases in TCA cycle inter-
mediates such as cis-aconitate have been shown to decrease in
response to a reduction in fat intake(39). The reason for not
detecting differences in the percentage change of other urinary
metabolites is probably due to higher baseline concentrations
of these metabolites. Furthermore, the high inter-individual
variation for these metabolites may explain why the percentage
change for these metabolites was not different among the
three treatment arms.
In order to determine if habitual diet during the study per-
iod influenced gut tolerability or changes in faecal microbiota,
participants filled out 3-d records the week prior to initiating
each study arm. Of the dietary variables measured, reported
mean dietary total and saturated fat (g/d) were significantly
higher during the lead-in period before participants initiated
the placebo-control arm compared with the wash-out period
before participants initiated the high-BMO supplement arm.
Reported mean total energy intake was also higher between
these two periods; however, the differences were not statistic-
ally significant. There was not a difference in any dietary vari-
able between the period preceding the low-BMO and
placebo-control and high-BMO supplemental arms. These
observations are unsurprising since the supplemental arms
were not randomly assigned and probably due to performance
bias that is reduced with randomisation(40). The reason this
study administered the supplemental arms in the following
order: placebo-control, low BMO and high BMO was to
Table 8. Urinary metabolites measured at baseline (day 0) and day 11 for each supplement arm
(Mean values and standard deviations)
Placebo-control Low-BMO High-BMO
Mean SD Mean SD Mean SD
Cis-aconitate day 0 17·4 5·2 19·2 7·1 20·5 5·1
Cis-aconitate day 11 24·2a 9·6 20·8a,b 4·8 13·8b 5·5
Myo-inositol day 0 7·6 3·0 6·5 3·5 13·1 4·7
Myo-inositol day 11 9·7 6·9 6·8 4·3 12·5 3·3
1-Methylhistidine day 0 162·6 208·1 34·8 44·8 80·0 52·7
1-Methylhistidine day 11 100·7 75·3 84·9 132·4 64·3 63·1
4-Hydroxyphenylacetate day 0 11·1 5·6 9·0 2·5 8·5 4·1
4-Hydroxyphenylacetate day 11 8·9a 3·2 8·3a,b 4·1 4·4b 2·0
2-Oxoglutarate day 0 12·1 5·7 10·2 6·5 8·3 2·9
2-Oxoglutarate day 11 10·7 5·5 7·2 3·7 6·7 3·3
Mannitol day 0 28·2 27·5 11·1 4·4 39·1 45·7
Mannitol day 11 18·6a,b 5·5 9·9a 6·1 39·1b 31·7
BMO, bovine milk oligosaccharides.
a,b Mean values with unlike superscript letters were significantly different (P < 0·05).
Fig. 5. Percentage change between day 11 and day 0 for urinary
cis-aconitate, myo-inositol, 4-hydroxyphenylacetate, 2-oxoglutarate and man-
nitol across all three supplement arms: placebo-control (□), low-bovine milk
oligosaccharide (BMO) ( ) and high-BMO (■). Values are means (n 7 per sup-
plemental arm), with standard deviations represented by vertical bars. The
mean percentage change for urinary cis-aconitate was significantly different
in response to the high-BMO compared with the placebo-control (P < 0·05).
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limit any anticipated carry-over effects by BMO on faecal
microbiota or bacterial metabolism. This study is the first to
establish that 2 weeks is a sufficient washout period for the
intake of BMO.
Ten daily doses of BMO did not substantially change the
overall faecal microbial ecology of these healthy adults. This
result is not surprising considering that diverse communities
found in healthy human adults are stable and resistant to
change(41). Indeed, the lack of substantial change confirms
that BMO supplementation is safe and tolerable. The results
further suggest that if the intent of BMO supplementation is
to change microbial populations, then the BMO will need to
be paired with an appropriate probiotic that avidly consumes
BMO. It is possible that BMO supplementation alone affects
faecal microbial function, rather than overall microbe popula-
tions. In a study of supplementation with fermented milk
strains, there was no treatment effect on the composition of
bacterial species or in the proportional representation of
genes encoding known enzymes; however, with RNA sequen-
cing, significant treatment effects were revealed for numerous
metabolic pathways(42). In other words, the bacterial species
present did not change in number, but their functions changed
significantly. Whether or not BMO supplementation alone
affects bacterial function is a question that requires further
exploration.
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